These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30953275)

  • 1. The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury.
    Brandolini L; Grannonico M; Bianchini G; Colanardi A; Sebastiani P; Paladini A; Piroli A; Allegretti M; Varrassi G; Di Loreto S
    Neurotox Res; 2019 Jul; 36(1):163-174. PubMed ID: 30953275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DF3016A induces increased BDNF transcription in ischemic neuroinflammation injury.
    Grannonico M; Brandolini L; Varrassi G; Sebastiani P; Colanardi A; Paladini A; Piroli A; Allegretti M; Di Loreto S
    Brain Res; 2020 Dec; 1748():147057. PubMed ID: 32898508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5aR antagonist inhibits occurrence and progression of complement C5a induced inflammatory response of microglial cells through activating p38MAPK and ERK1/2 signaling pathway.
    Liu Y; Xu SQ; Long WJ; Zhang XY; Lu HL
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7994-8003. PubMed ID: 30536348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation.
    Tang M; Zhang K; Li Y; He QH; Li GQ; Zheng QY; Zhang KQ
    Int Urol Nephrol; 2018 Aug; 50(8):1545-1553. PubMed ID: 29594894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C5a/C5aR pathway accelerates renal ischemia-reperfusion injury by downregulating PGRN expression.
    Zhang K; Li GQ; He QH; Li Y; Tang M; Zheng QY; Xu GL; Zhang KQ
    Int Immunopharmacol; 2017 Dec; 53():17-23. PubMed ID: 29031143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C5a/C5aR Pathway Plays a Vital Role in Brain Inflammatory Injury via Initiating Fgl-2 in Intracerebral Hemorrhage.
    Yuan B; Fu F; Huang S; Lin C; Yang G; Ma K; Shi H; Yang Z
    Mol Neurobiol; 2017 Oct; 54(8):6187-6197. PubMed ID: 27709492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C5a alters blood-brain barrier integrity in experimental lupus.
    Jacob A; Hack B; Chiang E; Garcia JG; Quigg RJ; Alexander JJ
    FASEB J; 2010 Jun; 24(6):1682-8. PubMed ID: 20065106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor.
    D'Angelo R; Mangini M; Fonderico J; Fulle S; Mayo E; Aramini A; Mariggiò S
    Biomed Pharmacother; 2020 Mar; 123():109764. PubMed ID: 31901551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.
    Lei YC; Lu CL; Chen L; Ge K; Yang LL; Li W; Wu YH
    World J Gastroenterol; 2016 Dec; 22(46):10148-10157. PubMed ID: 28028363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement C5a-C5aR interaction enhances MAPK signaling pathway activities to mediate renal injury in trichloroethylene sensitized BALB/c mice.
    Zhang JX; Zha WS; Ye LP; Wang F; Wang H; Shen T; Wu CH; Zhu QX
    J Appl Toxicol; 2016 Feb; 36(2):271-84. PubMed ID: 26095957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complement component C5a receptor mediates pain and inflammation in a postsurgical pain model.
    Liang DY; Li X; Shi X; Sun Y; Sahbaie P; Li WW; Clark DJ
    Pain; 2012 Feb; 153(2):366-372. PubMed ID: 22137294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of rat C5a anaphylatoxin receptor (C5aR): cloning of rat C5aR cDNA and study of C5aR expression by rat astrocytes.
    Sayah S; Patte C; Gasque P; Chan P; Ischenko A; Vaudry H; Fontaine M
    Brain Res Mol Brain Res; 1997 Sep; 48(2):215-22. PubMed ID: 9332718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice.
    Li L; Xiong ZY; Qian ZM; Zhao TZ; Feng H; Hu S; Hu R; Ke Y; Lin J
    Neurobiol Dis; 2014 Jun; 66():74-82. PubMed ID: 24607885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth.
    Pedroni SM; Gonzalez JM; Wade J; Jansen MA; Serio A; Marshall I; Lennen RJ; Girardi G
    Biochim Biophys Acta; 2014 Jan; 1842(1):107-15. PubMed ID: 24184716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated complement C5a receptor expression on neurons and glia in astrocyte-targeted interleukin-3 transgenic mice.
    Paradisis PM; Campbell IL; Barnum SR
    Glia; 1998 Nov; 24(3):338-45. PubMed ID: 9775985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal expression of a functional receptor for the C5a complement activation fragment.
    O'Barr SA; Caguioa J; Gruol D; Perkins G; Ember JA; Hugli T; Cooper NR
    J Immunol; 2001 Mar; 166(6):4154-62. PubMed ID: 11238666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury.
    De Hoog VC; Timmers L; Van Duijvenvoorde A; De Jager SC; Van Middelaar BJ; Smeets MB; Woodruff TM; Doevendans PA; Pasterkamp G; Hack CE; De Kleijn DP
    Cardiovasc Res; 2014 Sep; 103(4):521-9. PubMed ID: 24935433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C5a and pain development: An old molecule, a new target.
    Quadros AU; Cunha TM
    Pharmacol Res; 2016 Oct; 112():58-67. PubMed ID: 26855316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
    Nitta H; Wada Y; Kawano Y; Murakami Y; Irie A; Taniguchi K; Kikuchi K; Yamada G; Suzuki K; Honda J; Wilson-Morifuji M; Araki N; Eto M; Baba H; Imamura T
    Clin Cancer Res; 2013 Apr; 19(8):2004-13. PubMed ID: 23287562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation.
    Baelder R; Fuchs B; Bautsch W; Zwirner J; Köhl J; Hoymann HG; Glaab T; Erpenbeck V; Krug N; Braun A
    J Immunol; 2005 Jan; 174(2):783-9. PubMed ID: 15634899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.